Dragonfly Therapeutics, Inc. Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies that harness the immune system through multispecific antibody constructs. The company pursues both wholly owned clinical assets and a broad pipeline of preclinical candidates, supported by collaborations across multiple disease areas with partners including Merck, AbbVie, Gilead and Bristol Myers Squibb. Headquartered in Waltham, Massachusetts, Dragonfly operates within the biotechnology research industry as a clinical-stage innovator pursuing immune-engaging therapies. Its collaborations with large pharmaceutical companies indicate an emphasis on advancing programs through external partnerships. In 2024, the company announced leadership appointments, naming Susan Altschuller as chief financial officer and as co-founder and chief executive officer.